A recent analysis of all relevant published studies reveals a lack of evidence to determine the dosing, safety, and efficacy of medical marijuana or cannabis-containing products for managing symptoms experienced by children with cancer.
Bristol Myers Squibb reports 6% drop in Q2 2023 revenues
BMS updated its 2023 guidance, with the total revenues now expected to see a low single-digit reduction. Credit: Tada Images / Shutterstock.com. Bristol Myers Squibb